BRAF mutation in thyroid cancer.

By Michael Mingzhao Xing. Endocrine-Related Cancer, 2005

1,333 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Oncology

View Paper: https://www.semanticscholar.org/paper/3836a3bb83650d36a3a8f7b2133180953273ca08

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. Y. Nikiforov
2. M. Nikiforova
3. Mingzhao Xing

In Oncology

1. K. Flaherty
2. Mingzhao Xing
3. Y. Nikiforov
4. M. Nikiforova
5. D. Sidransky

Citations in the corpus

• Phase II trial of sorafenib in advanced thyroid cancer. (2008, background): “In thyroid cancer, BRAF has been found in 29% to 69% of papillary thyroid cancers(13,15,16) and has been associated with aggressive features including extrathyroidal extension and advanced stage.(17,18) RAS mutations and RET/PTC translocations associated with some thyroid cancers also result in aber”
• MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. (2008, background): “Of those, the association between BRAF mutation and tumor recurrence and treatment failure has produced the most substantial effect on clinical management of patients with thyroid cancer (34).”
• 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer (2009, neutral): “The BRAF mutation is found in *80% of these tumors (156,466).”
• Molecular genetics and diagnosis of thyroid cancer (2011, background): “The BRAF Val600Glu amino acid substitution is the most frequent genetic alteration in papillary thyroid cancer, being found in 40–45% of these tumors”
• Association Between BRAF V600E Mutation and Mortality in Patients With Papillary Thyroid Cancer (2013, background): “The T1799A nucleotide transversion in the BRAF gene (NM_004333) is a prominent oncogenic mutation in PTC(6-11) and occurs, on average, in 45% of cases.(12) This mutation causes a valine– to–glutamic acid change in codon 600 of the BRAF protein, resulting in BRAF V600E, which possesses elevated serin”
• Pathogenetic mechanisms in thyroid follicular-cell neoplasia (2006, background): “Indeed, exclusive, non-overlapping, activating events that involve the genes RET , NTRK1 (neurotrophic tyrosine kinase receptor 1), BRAF or Ras are detectable in nearly 70% of all case”